Actionable news
All posts from Actionable news
Actionable news in BLCM: BELLICum PHARMACEUTICALS Inc,

Bellicum Pharma's lead product candidate shows positive results in Phase 1/2 study in kids with blood cancers

Interim results from a Phase 1/2 clinical trial, BP-004, assessing Bellicum Pharmaceuticals' (NASDAQ:BLCM) lead product candidate, BPX-501, in children will certain blood cancers show a highly encouraging treatment benefit. The data were presented at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation in Valencia, Spain.

In the ongoing BP-004 study, malignant and nonmalignant pediatric patients receive a T cell-depleted hematopoietic stem cell transplant (HSCT) followed by an add-back of...